Drugs /

propranolol

Back to Drugs List

Overview

NCI Definition [1]:
A synthetic, nonselective beta-adrenergic receptor blocker with antianginal, antiarrhythmic, antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby causing negative chronotropic and inotropic effects leading to a reduction in cardiac output.

Clinical Trials

View Clinical Trials for propranolol

Propranolol has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating propranolol, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open).

PD-L1 Expression (CPS >= 10) is the most frequent biomarker inclusion criterion for propranolol clinical trials.

Bladder urothelial carcinoma, esophageal adenocarcinoma, and hemangioendothelioma are the most common diseases being investigated in propranolol clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Propranolol
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating propranolol and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
propanalol, propranolol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-2-propanol, propranolol [chemical/ingredient], propanolol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, propranolol (product), propanolol, propranolol, β-propranolol, propranololo, propranolol (substance), propranololum, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, beta-propranolol, 2-propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-
NCIT ID [1]:
C62073
SNOMED ID [1]:
C-80450

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.